Arnulf, B., Lambert, J., Karlin, L., Touzeau, C., Decaux, O., Perrot, A., Petillon, M., Caillot, D., Manier, S., Colella, J. M. S. D., Mohty, M., Vincent, L., Merzoug, K. B., Leleu, X., Hulin, C., Loschi, M., Montes, L., Chalopin, T., Chateleix, C., Bigenwald, C., Eveillard, J., Guillermin, Y., Jardin, F., Talbot, A., Lazareth, A., Bastie, J., Harel, S., Corre, J., Houot, R., Moya, N., Bories, P., Cazaubiel, T., Bigot, N., Facon, T., Avet-Loiseau, H., Ferment, B., Moreau, P. (2025). Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry. Blood. https://doi.org/10.1182/blood-2025-4076